Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Mehmet Samur

Mehmet Samur

PhD
Dana-Farber Cancer Institute
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more 13:45
Defining high-risk myeloma in the era of immune therapies: progress made, unmet needs & more
Francesco Maura et al. • 24 Oct 2025
Advancing the understanding of the biology of extramedullary disease in myeloma 2:24
Advancing the understanding of the biology of extramedullary disease in myeloma
Mehmet Samur • 19 May 2025
The value of whole genome sequencing in multiple myeloma 1:53
The value of whole genome sequencing in multiple myeloma
Mehmet Samur • 19 May 2025
Highlights from a session on advances in myeloma biology at COMy 2025 2:45
Highlights from a session on advances in myeloma biology at COMy 2025
Mehmet Samur • 19 May 2025
Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more
Faith Davies et al. • 4 Nov 2024
Antigen loss in patients with myeloma receiving immunotherapy 1:41
Antigen loss in patients with myeloma receiving immunotherapy
Mehmet Samur • 26 Sep 2024
Investigating genomic evolution at the time of relapse in multiple myeloma 1:23
Investigating genomic evolution at the time of relapse in multiple myeloma
Mehmet Samur • 26 Sep 2024
Improving the identification of patients with high-risk multiple myeloma 1:36
Improving the identification of patients with high-risk multiple myeloma
Mehmet Samur • 10 Dec 2022
Inherited predispositions to multiple myeloma 1:34
Inherited predispositions to multiple myeloma
Mehmet Samur • 10 Dec 2022
Genomic factors impacting survival in patients with myeloma without known cytogenetic risk features 2:37
Genomic factors impacting survival in patients with myeloma without known cytogenetic risk features
Mehmet Samur • 10 Dec 2022
Processes leading to the development of hyperdiploidy in multiple myeloma 3:00
Processes leading to the development of hyperdiploidy in multiple myeloma
Mehmet Samur • 10 Dec 2022
Investigating the mechanisms of initial & acquired resistance to BCMA CAR-T therapy in myeloma 1:59
Investigating the mechanisms of initial & acquired resistance to BCMA CAR-T therapy in myeloma
Mehmet Samur • 10 Dec 2022
Myeloma: BCMA loss as an escape mechanism 3:32
Myeloma: BCMA loss as an escape mechanism
Mehmet Samur • 6 May 2021
Combating loss of BCMA 2:21
Combating loss of BCMA
Mehmet Samur • 6 May 2021
Predicting outcomes with WGS in multiple myeloma 4:27
Predicting outcomes with WGS in multiple myeloma
Mehmet Samur • 8 Dec 2020
Biallelic BCMA loss causes anti-BCMA CAR-T resistance in myeloma 4:35
Biallelic BCMA loss causes anti-BCMA CAR-T resistance in myeloma
Mehmet Samur • 8 Dec 2020
The content of VJHemOnc is intended for healthcare professionals